Marginal Zone

Cartootorial: Food-allergic patients often experience anxiety about the possibility of a life-threatening reaction from an accidental exposure.1 While FDA-approved therapies to prevent this remain limited, anti-IgE biologics have shown promise for this indication.1,2,3 As monotherapy, omalizumab and a similar drug, TNX-901, significantly increased the reaction threshold in peanut-allergic patients from

https://www.annallergy.org/article/S1081-1206(23)00127-8/fulltext?rss=yes

Source: Annals of Allergy, Asthma and Immunology - June 30, 2023 Category: Allergy & Immunology Authors: Erin L. Reigh Tags: Marginal Zone Source Type: research